These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 28008252)

  • 1. Nanoscaled hydrated antimony (V) oxide as a new approach to first-line antileishmanial drugs.
    Franco AM; Grafova I; Soares FV; Gentile G; Wyrepkowski CD; Bolson MA; Sargentini É; Carfagna C; Leskelä M; Grafov A
    Int J Nanomedicine; 2016; 11():6771-6780. PubMed ID: 28008252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polarity-sensitive nanocarrier for oral delivery of Sb(V) and treatment of cutaneous leishmaniasis.
    Lanza JS; Fernandes FR; Corrêa-Júnior JD; Vilela JM; Magalhães-Paniago R; Ferreira LA; Andrade MS; Demicheli C; Melo MN; Frézard F
    Int J Nanomedicine; 2016; 11():2305-18. PubMed ID: 27307731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance.
    Dzamitika SA; Falcão CA; de Oliveira FB; Marbeuf C; Garnier-Suillerot A; Demicheli C; Rossi-Bergmann B; Frézard F
    Chem Biol Interact; 2006 Apr; 160(3):217-24. PubMed ID: 16524568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination oral therapy against Leishmania amazonensis infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine.
    Carregal VM; Lanza JS; Souza DM; Islam A; Demicheli C; Fujiwara RT; Rivas L; Frézard F
    Parasitol Res; 2019 Oct; 118(10):3077-3084. PubMed ID: 31401656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of antimony complexes of yeast mannan and mannan derivatives and their effect on Leishmania-infected macrophages.
    Cantos G; Barbieri CL; Iacomini M; Gorin PA; Travassos LR
    Biochem J; 1993 Jan; 289 ( Pt 1)(Pt 1):155-60. PubMed ID: 8424752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meglumine antımoniate-TiO2@Ag nanoparticle combinations reduce toxicity of the drug while enhancing its antileishmanial effect.
    Abamor ES; Allahverdiyev AM; Bagirova M; Rafailovich M
    Acta Trop; 2017 May; 169():30-42. PubMed ID: 28111133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and characterization of bismuth(III) and antimony(V) porphyrins: high antileishmanial activity against antimony-resistant parasite.
    Gomes ML; DeFreitas-Silva G; dos Reis PG; Melo MN; Frézard F; Demicheli C; Idemori YM
    J Biol Inorg Chem; 2015 Jul; 20(5):771-9. PubMed ID: 25929728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1.
    Mandal G; Mandal S; Sharma M; Charret KS; Papadopoulou B; Bhattacharjee H; Mukhopadhyay R
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003500. PubMed ID: 25714343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity.
    Borborema SE; Osso Junior JA; Andrade Junior HF; Nascimento Nd
    Rev Soc Bras Med Trop; 2016 Apr; 49(2):196-203. PubMed ID: 27192589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility.
    Barrera MC; Rojas LJ; Weiss A; Fernandez O; McMahon-Pratt D; Saravia NG; Gomez MA
    Acta Trop; 2017 Dec; 176():355-363. PubMed ID: 28843396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraspecies susceptibility of Leishmania (Viannia) braziliensis to antileishmanial drugs: Antimony resistance in human isolates from atypical lesions.
    Rugani JN; Quaresma PF; Gontijo CF; Soares RP; Monte-Neto RL
    Biomed Pharmacother; 2018 Dec; 108():1170-1180. PubMed ID: 30372818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2'-Hydroxyflavanone activity in vitro and in vivo against wild-type and antimony-resistant Leishmania amazonensis.
    Gervazoni LFO; Gonçalves-Ozório G; Almeida-Amaral EE
    PLoS Negl Trop Dis; 2018 Dec; 12(12):e0006930. PubMed ID: 30521527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-leishmanial activity of heteroleptic organometallic Sb(v) compounds.
    Ali MI; Rauf MK; Badshah A; Kumar I; Forsyth CM; Junk PC; Kedzierski L; Andrews PC
    Dalton Trans; 2013 Dec; 42(48):16733-41. PubMed ID: 24077559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimony susceptibility of Leishmania isolates collected over a 30-year period in Algeria.
    Eddaikra N; Ait-Oudhia K; Kherrachi I; Oury B; Moulti-Mati F; Benikhlef R; Harrat Z; Sereno D
    PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006310. PubMed ID: 29561842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease.
    Grogl M; Thomason TN; Franke ED
    Am J Trop Med Hyg; 1992 Jul; 47(1):117-26. PubMed ID: 1322070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition of antimony in rhesus monkeys infected with Leishmania braziliensis and treated with meglumine antimoniate.
    Friedrich K; Vieira FA; Porrozzi R; Marchevsky RS; Miekeley N; Grimaldi G; Paumgartten FJ
    J Toxicol Environ Health A; 2012; 75(2):63-75. PubMed ID: 22129235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action.
    Sereno D; Cavaleyra M; Zemzoumi K; Maquaire S; Ouaissi A; Lemesre JL
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3097-102. PubMed ID: 9835497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complexes of different nitrogen donor heterocyclic ligands with SbCl3 and PhSbCl2 as potential antileishmanial agents against Sb(III)-sensitive and -resistant parasites.
    Lizarazo-Jaimes EH; Reis PG; Bezerra FM; Rodrigues BL; Monte-Neto RL; Melo MN; Frézard F; Demicheli C
    J Inorg Biochem; 2014 Mar; 132():30-6. PubMed ID: 24412095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycaprolactone Antimony Nanoparticles as Drug Delivery System for Leishmaniasis.
    Sousa-Batista AJ; Cerqueira-Coutinho C; do Carmo FS; Albernaz MS; Santos-Oliveira R
    Am J Ther; 2019; 26(1):e12-e17. PubMed ID: 30601770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.
    Rojas R; Valderrama L; Valderrama M; Varona MX; Ouellette M; Saravia NG
    J Infect Dis; 2006 May; 193(10):1375-83. PubMed ID: 16619185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.